Pfizer buys Array BioPharma in $11.4bn deal
Executive Summary
In an effort to expand its cancer offerings with targeted therapies, Pfizer Inc. is paying $11.4bn in cash ($48 per share; a 66% premium) to acquire Array BioPharma Inc.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Drug Discovery Tools
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Includes Contract
- Payment Includes Cash
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice